Muse cells are nontumorigenic pluripotent stem cells present in adult tissues discovered by Mari DEZAWA at Tohoku University in 2010. Mitsubishi Life Sciences Institute has acquired this technology and carries out clinical trials targeting acute myocardial infarction since January 2018. The company announced on December 20 that they have started clinical trials with Muse cells type CL 2020 for the treatment of Epidermolysis bullosa, a genetic disease which leads to easy blistering of skin and mucous membranes.
Mitsubishi Life Sciences Institute news release, December 20, 2018
Mitsubishi Life Sciences Institute to begin clinical trials on Muse cell therapy for Epidermolysis bullosa